Fig. 6

PPARγ antagonism dampens the effect of miR-130b inhibition on VEGF-A/BCL-2-mediated apoptosis. a Requirement of PPARγ in miR-130b mediated expressions of VEGF-A and BCL-2. b Bevacizumab down-regulated BCL-2 in a time- and c dose-dependent manner. d Interaction between PPARγ and VEGF-A by immunoprecipitation. e Interaction between VEGF-A and BCL-2 by immunoprecipitation. f Apoptosis was increased by anti-miR-130b but decreased by GW9662. Attenuation of the effect of miR-130b inhibition on apoptosis by GW9662. Scale bar, 100 μm. Anti-M: anti-miR-130b; bev.: bevacizumab; TUNEL, terminal deoxynucleotidyl transferase-mediated uridine 5’-triphosphate-biotin nick end labeling. Each bar represents the mean ± SD. Results are representative of three independent experiments. *p < 0.05, #p < 0.001